Literature DB >> 23853171

Physical presence of nor-binaltorphimine in mouse brain over 21 days after a single administration corresponds to its long-lasting antagonistic effect on κ-opioid receptors.

Kshitij A Patkar1, Jinhua Wu, Michelle L Ganno, Harminder D Singh, Nicolette C Ross, Khampaseuth Rasakham, Lawrence Toll, Jay P McLaughlin.   

Abstract

In the mouse 55°C warm-water tail-withdrawal assay, a single administration of nor-binaltorphimine (nor-BNI; 10 mg/kg i.p.) antagonized κ-opioid receptor (KOR) agonist-induced antinociception up to 14 days, whereas naloxone (10 mg/kg i.p.)-mediated antagonism lasted less than 1 day. In saturation binding experiments, mouse brain membranes isolated and washed 1 or 7 (but not 14) days after nor-BNI administration demonstrated a significant time-dependent decrease in maximal KOR agonist [(3)H]U69,593 binding. To determine whether brain concentrations of nor-BNI were sufficient to explain the antagonism of KOR-mediated antinociception, mouse blood and perfused brain were harvested at time points ranging from 30 minutes to 21 days after a single administration and analyzed for the presence of nor-BNI using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Nor-BNI was detected in the perfused brain homogenate up to 21 days after administration (30 nmol i.c.v. or 10 mg/kg i.p.). Subsequent experiments in which nor-BNI was administered at doses estimated from the amounts detected in the brain homogenates isolated from pretreated mice over time demonstrated significant antagonism of U50,488 antinociception in a manner consistent with the magnitude of observed KOR antagonism. The dose (1.4 nmol) approximating the lowest amount of nor-BNI detected in brain on day 14 did not antagonize U50,488-induced antinociception, consistent with the absence of U50,488 antagonism observed in vivo at this time point after pretreatment. Overall, the physical presence of nor-BNI in the mouse brain paralleled its in vivo pharmacological profile, suggesting physicochemical and pharmacokinetic properties of nor-BNI may contribute to the prolonged KOR antagonism.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23853171     DOI: 10.1124/jpet.113.206086

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests.

Authors:  Peng Huang; Tatyana Yakovleva; Jane V Aldrich; Julia Tunis; Christopher Parry; Lee-Yuan Liu-Chen
Journal:  Neurosci Lett       Date:  2016-01-15       Impact factor: 3.046

2.  Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.

Authors:  Kia J Jackson; Asti Jackson; F Ivy Carroll; M Imad Damaj
Journal:  Neuropharmacology       Date:  2015-06-01       Impact factor: 5.250

3.  Long-Term Reduction of Kappa Opioid Receptor Function by the Biased Ligand, Norbinaltorphimine, Requires c-Jun N-Terminal Kinase Activity and New Protein Synthesis in Peripheral Sensory Neurons.

Authors:  Raehannah J Jamshidi; Laura C Sullivan; Blaine A Jacobs; Teresa A Chavera; Kelly A Berg; William P Clarke
Journal:  J Pharmacol Exp Ther       Date:  2016-09-07       Impact factor: 4.030

4.  Characterization of BU09059: a novel potent selective κ-receptor antagonist.

Authors:  Joseph J Casal-Dominguez; Daniel Furkert; Mehrnoosh Ostovar; Linnea Teintang; Mary J Clark; John R Traynor; Stephen M Husbands; Sarah J Bailey
Journal:  ACS Chem Neurosci       Date:  2014-01-28       Impact factor: 4.418

5.  Pharmacodynamic Relationships between Duration of Action of JDTic-like Kappa-Opioid Receptor Antagonists and Their Brain and Plasma Pharmacokinetics in Rats.

Authors:  S Michael Owens; Gerald T Pollard; James L Howard; Timothy R Fennell; Rodney W Snyder; F Ivy Carroll
Journal:  ACS Chem Neurosci       Date:  2016-10-04       Impact factor: 4.418

6.  Dissociating Motivational From Physiological Withdrawal in Alcohol Dependence: Role of Central Amygdala κ-Opioid Receptors.

Authors:  Jessica L Kissler; Brendan M Walker
Journal:  Neuropsychopharmacology       Date:  2015-06-24       Impact factor: 7.853

7.  Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice.

Authors:  Adam L Halberstadt; James Hyun; Michael A Ruderman; Susan B Powell
Journal:  Pharmacol Biochem Behav       Date:  2016-05-26       Impact factor: 3.533

8.  BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.

Authors:  T V Khroyan; J Wu; W E Polgar; G Cami-Kobeci; N Fotaki; S M Husbands; L Toll
Journal:  Br J Pharmacol       Date:  2014-11-05       Impact factor: 8.739

9.  κ-Opioid receptors are not necessary for the antidepressant treatment of neuropathic pain.

Authors:  Salim Megat; Yohann Bohren; Stephane Doridot; Claire Gaveriaux-Ruff; Brigitte L Kieffer; Marie-José Freund-Mercier; Ipek Yalcin; Michel Barrot
Journal:  Br J Pharmacol       Date:  2014-12-01       Impact factor: 8.739

10.  Maturational alterations in constitutive activity of medial prefrontal cortex kappa-opioid receptors in Wistar rats.

Authors:  Sunil Sirohi; Brendan M Walker
Journal:  J Neurochem       Date:  2015-09-11       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.